Pfizer Expands Vaccine Access
Pfizer has expanded its humanitarian assistance program to enable broader access to its vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13 – valent, adsorbed]), in emergency settings by offering its new multi-dose vial at $3.10 per dose, the lowest prevailing global price currently. The company said it will also donate all sales proceeds for the first year of this program to humanitarian groups that are reaching vulnerable populations in emergency settings. In the immediate term, Pfizer said it will provide a short-term donation of the single-dose vial of Prevenar 13.
Starting in 2017, refugees can receive the newest multi-dose vial version of Prevenar 13. This presentation is scheduled to be introduced early next year and contains four doses of Prevenar 13 in the same-sized vial that currently contains a single dose.
Prevenar 13 was approved in the European Union in December 2009 for use in infants and young children and was approved for such use in more than 150 countries worldwide, including the US, Canada, Australia, and Japan.